Top

Published in:

01-03-2011

Current knowledge on diagnosis and staging of neuroendocrine tumors

Authors: Kjell Öberg, Daniel Castellano

Published in: Cancer and Metastasis Reviews | Special Issue 1/2011

Abstract

Neuroendocrine tumors (NETs) consist of a heterogeneous group of malignancies with various clinical presentations and growth rates. The incidence has been estimated to 2.5–5 per 100,000 people per year and prevalence of 35 per 100,000. The largest group is the gastroenteropancreatic NETs. Small intestinal NETs are the most common followed by pancreatic NETs in the gastrointestinal tract. A classification system (World Health Organization) was established in year 2000 and recently updated in 2010, taking into consideration the histopathology and tumor biology of the tumors. To further refine the classification a “tumor node metastasis” staging has been suggested by the European Neuroendocrine Tumor Society. The same organization has also proposed a grading system (G1, G2, and G3). The diagnosis of a NET is based on histopathology on tumor specimens, circulating biomarkers as well as imaging. Traditional radiology, such as computerized tomography and magnetic resonance imaging, is still the basis but is complemented with somatostatin receptor scintigraphy and positron emission tomography with specific isotopes such ⁶⁸Ga-DOTA-octreotate, F18-dopamine, or C11-5 hydroxytryptamine. Molecular imaging will increase in importance in the near future. There is still an unmet need for more sensitive biomarkers for diagnosis and follow-up.

Lubarsch, O. (1867). Ueber den primaren Krebs des Ileum, nebst Bemerkungen über das gleichzeitige Vorkommen von Krebs und Tuberkuolose. Virchow Archiv Pathol Anatom Physiol Klin Med, 111, 280–317.CrossRef

Modlin, I. M., Oberg, K., Chung, D. C., et al. (2008). Gastroenteropancreatic neuroendocrine tumours. The Lancet Oncology, 9(1), 61–72.PubMedCrossRef

Modlin, I. M., Lye, K. D., & Kidd, M. (2003). A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 97(4), 934–59.PubMedCrossRef

Modlin, I. M., Kidd, M., Latich, I., et al. (2005). Current status of gastrointestinal carcinoids. Gastroenterology, 128(6), 1717–51.PubMedCrossRef

Oberg, K. (2005). Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET’s). Roczniki Akademii Medycznej w Bialymstoku, 50, 62–8.PubMed

Reubi, J. C., & Waser, B. (2003). Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. European Journal of Nuclear Medicine and Molecular Imaging, 30(5), 781–93.PubMedCrossRef

Guillemin, R. (2005). Hypothalamic hormones a.k.a. hypothalamic releasing factors. The Journal of Endocrinology, 184(1), 11–28.PubMedCrossRef

Oberg, K. E., Reubi, J. C., Kwekkeboom, D. J., et al. (2010). Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology, 139(3), 742–53. 753 e1.PubMedCrossRef

Welin, S. V., Janson, E. T., Sundin, A., et al. (2004). High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. European Journal of Endocrinology, 151(1), 107–12.PubMedCrossRef

10.

Waldherr, C., Pless, M., Maecke, H. R., et al. (2002). Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. Journal of Nuclear Medicine, 43(5), 610–6.PubMed

11.

Oberg, K. (1999). Neuroendocrine gastrointestinal tumors—a condensed overview of diagnosis and treatment. Annals of Oncology, 10(Suppl 2), S3–8.PubMedCrossRef

12.

Stridsberg, M., Eriksson, B., Oberg, K., et al. (2003). A comparison between three commercial kits for chromogranin A measurements. The Journal of Endocrinology, 177(2), 337–41.PubMedCrossRef

13.

Eriksson, B., Arnberg, H., Oberg, K., et al. (1989). Chromogranins—new sensitive markers for neuroendocrine tumors. Acta Oncológica, 28(3), 325–9.PubMedCrossRef

14.

Leja, J., Essaghir, A., Essand, M., et al. (2009). Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Modern Pathology, 22(2), 261–72.PubMedCrossRef

15.

Duerr, E. M., Mizukami, Y., Ng, A., et al. (2008). Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer, 15(1), 243–56.PubMedCrossRef

16.

Kloppel, G., Perren, A., & Heitz, P. U. (2004). The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Annals of the New York Academy of Sciences, 1014, 13–27.PubMedCrossRef

17.

Ekeblad, S., Skogseid, B., Dunder, K., et al. (2008). Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clinical Cancer Research, 14(23), 7798–803.PubMedCrossRef

18.

Rindi, G., Kloppel, G., Alhman, H., et al. (2006). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv, 449(4), 395–401.PubMedCrossRef

19.

Rindi, G., Kloppel, G., Couvelard, A., et al. (2007). TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archiv, 451(4), 757–62.PubMedCrossRef

20.

Fischer, L., Kleeff, J., Esposito, I., et al. (2008). Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. The British Journal of Surgery, 95(5), 627–35.PubMedCrossRef

21.

Pape, U. F., Jann, H., Muller-Nordhorn, J., et al. (2008). Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer, 113(2), 256–65.PubMedCrossRef

22.

Eriksson, B., Oberg, K., & Stridsberg, M. (2000). Tumor markers in neuroendocrine tumors. Digestion, 62(Suppl 1), 33–8.PubMedCrossRef

23.

Oberg, K., Janson, E. T., & Eriksson, B. (1999). Tumour markers in neuroendocrine tumours. Italian Journal of Gastroenterology and Hepatology, 31(Suppl 2), S160–2.PubMed

24.

Leja, J., Nilsson, B., Yu, D., et al. (2010). Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability. PLoS ONE, 5(1), e8916.PubMedCrossRef

25.

Modlin, I. M., Gustafsson, B. I., & Kidd, M. (2007). Gastrointestinal carcinoid tumors. In C. W. Howden, J. Baillie, A. L. Buchman, D. C. Metz, & I. M. Modlin (Eds.), Advances in digestive disease (pp. 203–218). Bethesda: AGA Institute Press.

26.

Anderson, M. A., Carpenter, S., Thompson, N. W., et al. (2000). Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. The American Journal of Gastroenterology, 95(9), 2271–7.PubMedCrossRef

27.

Gibril, F., Reynolds, J. C., Doppman, J. L., et al. (1996). Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Annals of Internal Medicine, 125(1), 26–34.PubMed

28.

Adams, S., Baum, R., Rink, T., et al. (1998). Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. European Journal of Nuclear Medicine, 25(1), 79–83.PubMed

29.

Koopmans, K. P., de Vries, E. G., Kema, I. P., et al. (2006). Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. The Lancet Oncology, 7(9), 728–34.PubMedCrossRef

30.

Orlefors, H., Sundin, A., Garske, U., et al. (2005). Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. The Journal of Clinical Endocrinology and Metabolism, 90(6), 3392–400.PubMedCrossRef

31.

Koukouraki, S., Strauss, L. G., Georgoulias, V., et al. (2006). Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. European Journal of Nuclear Medicine and Molecular Imaging, 33(4), 460–6.PubMedCrossRef

Title: Current knowledge on diagnosis and staging of neuroendocrine tumors
Authors: Kjell Öberg
Daniel Castellano
Publication date: 01-03-2011
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue Special Issue 1/2011
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-011-9292-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2011

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

Gastroenteropancreatic neuroendocrine tumors. Where are we now?

Future perspectives on neuroendocrine tumors

Somatostatin analogs for the treatment of neuroendocrine tumors

Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer